COT Cotinga Pharmaceuticals Inc

Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced today that
it is extending the expiry date of 12,500,000 common share purchase warrants
(Warrants) issued as part of three tranches of a non-brokered private placement
on March 25, April 7, and April 21, 2011 respectively. Each Warrant entitled its
holder to purchase one Common Share of the Company at an exercise price of $0.30
per share for a period of 18 months from the date of issue.


"This amendment acknowledges the long term support of our investors from the
original private placement related to these warrants," said Dr. Wayne Danter,
President and Chief Executive Officer. "This amendment also recognizes the
potential future financing source represented by these warrants that can be
retained at a relatively low cost by the Company." 


Effective September 6, 2012, the Company amended the terms of the Warrants to
extend the original expiry date of the Warrants to 5:00 p.m. on October 31,
2013. Subsequently, effective October 29, 2013, the Company further amended the
terms of the Warrants to extend the expiry date of the Warrants to 5:00 p.m.
(Toronto time) on May 31, 2014 (the Expiry Date).


The Expiry Date is now being amended to extend it to 5:00 p.m. (Toronto time) on
March 15, 2016, (the New Expiry Date), provided that the New Expiry Date of the
Warrants will be accelerated to 21 days if, for any ten consecutive trading
days, the closing price of the Common Shares equals or exceeds $0.60. All other
previously amended and unamended terms and conditions of the Warrants remain
unchanged. 


The Company will deliver a Notice of Amendment reflecting the amended expiry
date to the registered holders of the Warrants.


About Critical Outcome Technologies Inc. (COTI) 

COTI is a leading-edge bioinformatics company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI'S proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective.


Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com
www.criticaloutcome.com

Cotinga Pharmaceuticals (TSXV:COT)
Historical Stock Chart
From May 2024 to Jun 2024

Cotinga Pharmaceuticals (TSXV:COT)
Historical Stock Chart
From Jun 2023 to Jun 2024